This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Helsinn Healthcare SA
Drug Names(s): R-1124
Description: Netupitant is a potent and selective NK-1 receptor antagonist.
Deal Structure: Netupitant was originally developed by Roche.
Helsinn and Roche
In May 2005, Helsinn healthcare and Roche announced the signing of a licensing agreement, granting Helsinn the worldwide rights for netupitant.
Partners: Roche Holding AG
Additional information available to subscribers only: